ID-PRESERVED
CARDINNOV
Research targeting development of innovative therapautic strategies in cardiovascular disease
ID-PRESERVED is an international collaborative project funded by the ERA4Health Partnership, and co-funded by the European Union, under the 2023 CardInnov Call: “Research targeting development of innovative therapeutic strategies in cardiovascular disease”
Advancing the Fight Against HFpEF with ID-PRESERVED
Understanding HFpEF: A Growing Global Challenge
Heart Failure with Preserved Ejection Fraction (HFpEF) is becoming the most prevalent form of heart failure worldwide. Despite its increasing impact, current management relies primarily on treating symptoms and underlying conditions, with limited evidence-based pharmacotherapies available. This highlights an urgent clinical need for innovative solutions.
The Challenge
HFpEF’s Complexity and Treatment Gap
One of the main obstacles in developing effective HFpEF therapies is its pathophysiological and etiological heterogeneity. This complexity makes it difficult to create targeted treatments.
Addressing this challenge requires:
- Personalized therapeutic strategies tailored to specific patient profiles.
- Identifying common mechanisms shared across HFpEF subtypes to develop more universal treatments.
The Role of Inflammation in HFpEF
Recent research suggests that exacerbated inflammatory responses may play a key role in many forms of HFpEF. However, the specific immunomodulatory mechanisms driving the disease remain poorly understood.
Personalized Medicine & Clonal Hematopoiesis
Age-related clonal hematopoiesis—a condition caused by acquired genetic mutations—has emerged as a powerful cardiovascular risk factor. It is associated with increased inflammation and a higher risk of atherosclerotic cardiovascular disease, opening doors for precision medicine approaches. However, its role in HFpEF remains unexplored.
ID-PRESERVED: A Collaborative Effort for Breakthroughs
To tackle these challenges, ID-PRESERVED unites leading researchers across Europe (Spain, France, Netherlands, Hungary, and Italy) in a transnational collaboration that brings together:
- Unique resources – including human cohorts, extensive datasets, and advanced mouse models of HFpEF.
- Multidisciplinary expertise – spanning clinical cardiology, experimental heart failure research, pharmacology, cardioimmunology, cardiogenetics, and clonal hematopoiesis.
Our Mission
Unlocking New Treatments for HFpEF
Identify
New inflammatory drivers of HFpEFnec.
Test
Whether they can be targeted with existing HFpEF treatments.
Develop
New anti-inflammatory therapies for HFpEF.
A Leap Forward in HFpEF Research
By uncovering novel mechanisms and potential therapeutic targets, ID-PRESERVED has the potential to revolutionize HFpEF treatment, leading to a significant scientific and socioeconomic impact.
Our Publications
Check our latest ID Preserved Cardionnov Publications
Clonal hematopoiesis in cardiovascular disease and therapeutic implications
- Nat Cardiovasc Res. 2022 Feb;1(2):116-124. doi: 10.1038/s44161-021-00015-3;
NASH triggers cardiometabolic HFpEF in aging mice
- Geroscience. 2024 Apr 17;
Association of baseline and longitudinal changes in insulin-like growth factor-binding protein-7 with the risk of incident heart failure: Data from the PREVEND study
- Eur J Heart Fail 2024 Jul 17. doi:10.1002/ejhf.3328;
Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome
- J Am Coll Cardiol. 2018 Feb 27;71(8):875-886. doi: 10.1016/j.jacc.2017.12.037;